Atalanta Therapeutics, a Boston-based developer of treatments for neurodegenerative diseases, has launched with a $110 million Series A from F-Prime Capital. The startup has also teamed up with fellow biotech companies Biogen and Genentech to develop drugs for certain diseases including Huntington's, Parkinson's and Alzheimer's.